Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Richard G. Vile, Victoria Roulstone, Kevin J. Harrington, Hardev Pandha, Sophia N. Karagiannis, C L White, Robert J. Harris, Johann S. de Bono, Alan Melcher, Katie Twigger, David Mansfield, James Spicer
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundOncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential
Autor:
Kate Newbold, Shreerang Bhide, Alan Melcher, Amy Trinh, KH Wong, Pablo Nenclares, Lucinda Gunn, Heba Soliman, Mateo Bover, Kevin J. Harrington, Christopher M. Nutting, Isla Leslie, Derfel Ap Dafydd
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundPrevious studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, including those treated with
Autor:
Jennifer Kingston, Anna Wilkins, Anguraj Sadanandam, Hannah Bye, David Mansfield, Jessica A. Downs, Elisa Fontana, A Noshirwani, Fiona Errington-Mais, Yatish Patil, Magnus T. Dillon, Katharina von Loga, Paul Carter, Kevin J. Harrington, Gift Nyamundanda, Daniel Bottomley, David Sebag-Montefiore, Sandra Demaria, Nicholas P. West, Chanthirika Ragulan, E Tinkler-Hundal, Alan Melcher
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundRectal cancers show a highly varied response to neoadjuvant radiotherapy/chemoradiation (RT/CRT) and the impact of the tumor immune microenvironment on this response is poorly understood. Current clinical tumor regression grading systems at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052136d6546eada06fa12d3ecaa8e106
https://eprints.whiterose.ac.uk/170165/30/e001717.full.pdf
https://eprints.whiterose.ac.uk/170165/30/e001717.full.pdf
Autor:
Robert H.I. Andtbacka, Frances A. Collichio, Gerald Downey, Kevin J. Harrington, Howard L. Kaufman, Mark R. Middleton, Katarina Ӧhrling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB
Autor:
Syed Haider, Robert S. Coffin, Eva Crespo-Rodriguez, Khin Thway, Richard Buus, Alan Melcher, Richard G. Vile, Harriet Whittock, Emmanuel C Patin, Galabina Bozhanova, Kate Newbold, Dae Kim, Katharina F. Bergerhoff, Malin Pedersen, Gareth Muirhead, Martin McLaughlin, Shane Foo, Kevin J. Harrington
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mut